Cancer clinical trials remain highly underrepresented from racial and ethnic minorities. The lack of diversity in clinical trials significantly impacts the generalizability of drug treatments approved for cancer patients. This review intends to discuss recent shifts in cancer clinical trials to increase equitable participation across all patient populations.

https://doi.org/10.1007/s12609-024-00526-5